1. 2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma. (September 2015) Authors: Wang, K.; Ganesan, S.; Johnson, A.; Sharman, J.P.; Chachoua, A.; Hirshfield, K.; Aisner, J.; Yelensky, R.; Lipson, D.; Elvin, J.A.; Chmielecki, J.; Stephens, P.J.; Ross, J.S.; Miller, V.A.; Ou, S.H.I.; Ali, S.M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S583 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB‐INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. (12th June 2019) Authors: Rogers, K.A.; Thompson, P.A.; Allan, J.N.; Coleman, M.; Sharman, J.P.; Cheson, B.D.; Izumi, R.; Frigault, M.M.; Quah, C.; Raman, R.K.; Wang, M.H.; Kipps, T.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA. (June 2017) Authors: Coleman, M.; Andorsky, D.J.; Yacoub, A.; Melear, J.M.; Kolibaba, K.S.; Brooks, H.D.; Bitran, J.D.; Fanning, S.R.; Lansigan, F.; Ricker, J.L.; Foon, K.A.; Llorente, M.; Li, J.; Sharman, J.P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES. (12th June 2019) Authors: Molina, A.; Shah, N.; Krishnan, A.Y.; Shah, N.D.; Burke, J.M.; Melear, J.M.; Spira, A.I.; Popplewell, L.L.; Andreadis, C.B.; Chhabra, S.; Sharman, J.P.; Kaufman, J.L.; Cohen, J.B.; Niesvizky, R.; Martin, T.G.; DiLea, C.; Kuriakose, J.; Matheny, S.L.; Leonard, J.P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 324 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. (June 2017) Authors: Sharman, J.P.; Brander, D.M.; Mato, A.; Kambhampati, S.; Burke, J.M.; Lansigan, F.; Schreeder, M.T.; Lunin, S.D.; Ghosh, N.; Zweibach, A.; Shtivelband, M.I.; Travis, P.M.; Chandler, J.; Kolibaba, K.S.; Sporteli, P.; Miskin, H.P.; Weiss, M.S.; Flinn, I.W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗